Poster Presentation Society of Obstetric Medicine of Australia and New Zealand ASM 2018

Recurrent fetal thyrotoxicosis in a woman with definitively treated Graves’ disease. (#65)

Michele Bardin 1 , Jennifer Conn 1 , Simon Forehan 1 , Elly McNamara
  1. The Royal Women's Hospital , Parkville, Victoria, Australia

Graves disease occurs in 0.2-0.4% of all pregnancies(1). TSH receptor antibodies (TRABs) can persist despite definitive treatment, with presence of TRABs in up to 40% of patients 5 years post thyroid ablation(2). Guidelines  recommend monitoring of TRAB titre if levels exceed three time the upper limit of normal during gestation as these levels have been shown to confer higher risk of neonatal thyrotoxicosis(3).

We present a case of fetal thyroxicosis in a 38 year old woman with a history of severe relapsing Graves’s hyperthyroidism complicated by ongoing opthalmopathy. Radioactive iodine treatment 20 years prior rendered her hypothyroid requiring thyroxine replacement. Two previous pregnancies were complicated with marked TRAB elevation(>20IU/L) and subsequent fetal thyrotoxicosis necessitating emergency caesarean sections at 35 and 36 weeks gestation. Both neonates were treated with carbimazole during the first weeks of life. In her 3rd pregnancy she was monitored from 10 weeks gestation with regular TRAB levels. CTG traces at 34 weeks gestation showed persistent fetal tachycardia of 200bpm, without of features of thyrotoxicosis on ultrasound. Carbimazole 10mg twice daily and propranolol 20mg twice daily was commenced, with the beta-blocker dosage being titrated against the CTG fetal heart rate. The fetal tachycardia resolved on treatment but by 36 weeks gestation ultrasound showed growth restriction, with the estimated fetal weight dropping from 65th to 35th centile, and associated oligohydramnios. The patient underwent an elective caesarean at 37 weeks. Biochemical neonatal thyrotoxicosis progressively worsened to day 3 post delivery (Table 1) consistent with reduced neonatal serum carbimazole concentration but ongoing TRAB activity (see table 1). Antithyroid drugs (ATDs) cross the placenta(4) and neonatal thyrotoxicosis may not become apparent until 2-5 days post birth when ATDs are cleared from the circulation. The neonate was commenced on carbimazole with good biochemical and clinical effect. This case demonstrates the need for recognition of TRAB status in women with definitively treated Graves’ disease as fetal hyperthyroidism may occur despite maternal euthyroidism (5). 



  1. Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol. 2013;1(3):238-49.
  2. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008;158(1):69-75.
  3. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315-89.
  4. Taylor PN, Vaidya B. Side Effects of Anti-Thyroid Drugs and Their Impact on the Choice of Treatment for Thyrotoxicosis in Pregnancy. Eur Thyroid J. 2012; 1(3):[176-85 pp.].
  5. Balucan FS, Morshed SA, Davies TF. Thyroid autoantibodies in pregnancy: their role, regulation and clinical relevance. J Thyroid Res. 2013;2013:182472.